Anti-PD-1/PD-L1 antibodies interrupt the immunosuppressive pathway induced by the interaction between the T cell coinhibitory receptor PD-1 and its ligand PD-L1, the latter of which is expressed in various cell types including immune and tumour cells [11–14]. Here, PDCD1 is linked to neoplasm.